申请人:Merck Sharp & Dohme, Ltd.
公开号:US05231102A1
公开(公告)日:1993-07-27
A class of 1,2,3,4-tetrahydroquinolines possessing at least one substituent, or a spirocyclic moiety, at the 4-position, and an acidic group or a group convertible thereto in vivo at the 2-position, are specific antagonists of N-methyl-D-aspartate (NMDA) receptors and are therefore useful in the treatment and/or prevention of neurodegenerative disorders.
一类1,2,3,4-四氢喹啉化合物,其在4位至少具有一个取代基或螺环结构基团,在2位具有一个酸性基团或可在体内转化为该基团,是N-甲基-D-天冬氨酸(NMDA)受体的特异性拮抗剂,因此在治疗和/或预防神经退行性疾病方面具有用途。